Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388665 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL2471302 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29617431 | 0.88 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL20552905 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29388144 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29988970 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29988323 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29723146 | 0.83 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL25366729 | 0.82 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL29988327 | 0.80 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | PIKE THERAPEUTICS INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | PIKE THERAPEUTICS INC (CA) | 2025-08-07 | — | — | US | disclosed |
| CN-119923256-A | Continuous delivery system comprising cannabinoids and medical uses thereof | 长矛治疗股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| CN-117545478-A | Transdermal pharmaceutical preparation for treating chronic pain | 长矛治疗股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117460503-A | Transdermal delivery of cannabidiol | 长矛治疗股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117337174-A | Transdermal pharmaceutical formulation comprising CBD or THC for the treatment of cancer | 长矛治疗股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| EP-4196113-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics, Inc. (CA) | 2023-06-21 | — | — | EP | disclosed |
| CN-116075296-A | Transdermal pharmaceutical preparation for treating multiple sclerosis | 长矛治疗股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916184-A | Transdermal and/or topical pharmaceutical formulations for the treatment of chronic pain comprising cannabidiol and/or tetrahydrocannabinol | 长矛治疗股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115884761-A | Transdermal pharmaceutical formulations of cannabinoids | 长矛治疗股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| EP-4110325-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2023-01-04 | — | — | EP | disclosed |
| US-20220347151-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS INC (CA) | 2022-11-03 | — | — | US | disclosed |
| WO-2022219468-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC. 1219014 B.C. LTD. (CA) | 2022-10-20 | — | — | WO | disclosed |
| CN-114555068-A | Transdermal administration of cannabidiol | 长矛治疗股份有限公司1219014 B.C.有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | SOST, CNR2, BHMT2 | CNR2 2/4885CNR1 25/4885 |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR2 2/4885CNR1 1/4885 |
| US-20220347151-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885 |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.